Counterfeit ‘Abhayrab’ Rabies Vaccine Batch Sparks Investigation in India

Rabies is one of those diseases where you simply cannot afford a slip‑up – a potent vaccine given in time can save a life, but a counterfeit dose can give a false sense of security and, in the worst case, turn a preventable tragedy into a fatal one.

In late April 2026, officers from the Delhi Police Crime Branch, together with officials from the Delhi Drugs Control Department, swooped on an unlicensed residential premise in Mukherjee Nagar. Inside they discovered dozens of vials that, at first glance, bore the batch number KE25012 of the legitimate Abhayrab rabies vaccine produced by the Human Biologicals Institute.

Four individuals were arrested on the spot. The seized vials were promptly sent to the Central Drugs Laboratory (CDL) in Kasauli for the mandatory potency test that every post‑exposure rabies shot must pass before reaching clinics.

The results were unsettling. The laboratory declared the samples “Not of Standard Quality” and labeled them “misbranded”. In plain language, the vials did not contain the amount of active antigen required to confer protection, and they were masquerading as an approved product.

What set the fake batch apart from the authentic one? Apart from the failed potency test, investigators noted a slew of discrepancies: the packaging material was thinner, the artwork on the label was slightly off‑centre, the QR‑code didn’t scan to the official verification portal, the cap colour differed, and the licence details printed on the label were either missing or inaccurate.

These findings have raised two urgent questions for health authorities. First, how did a counterfeit batch acquire the exact batch number of a genuine consignment? Second, and perhaps more alarming, is there any chance that someone who was bitten by a potentially rabid animal received one of these sub‑standard doses?

Rabies, once clinical symptoms appear, is almost invariably fatal. The World Health Organization recommends a series of post‑exposure prophylaxis injections – each one must contain a specific concentration of the rabage virus antigen to neutralise the pathogen before it reaches the nervous system. A compromised vaccine not only fails to protect the bite victim but also erodes public confidence in the vaccination programme.

The Central Drugs Standard Control Organisation (CDSCO) has now opened a formal inquiry. The probe will trace the entire supply chain – from the point of manufacture, through any intermediaries, right up to the unlicensed address where the vials were stored. Authorities are also reviewing the records of hospitals and clinics that may have ordered or received the suspect batch, to ensure that no patient has been inadvertently given a counterfeit shot.

Meanwhile, the government has urged anyone who received a rabies vaccine after a dog bite in the last six months to verify the batch number on the vial and report any doubts to their nearest health centre. The message is clear: better to double‑check than to assume.

As the investigation unfolds, it serves as a stark reminder of the importance of strict regulatory oversight, especially for life‑saving biologics. In a country where stray dogs are a common source of rabies exposure, the integrity of each vaccine vial can mean the difference between life and death.